Albany Molecular Research, Ranbaxy Laboratories, IBS Pharma, PhRMA and Globalpharma - People on the move
and Globalpharma have all had people on the move in the world of
pharmaceutical manufacturing.
Drug manufacturer Albany Molecular Research has created the new position of vice president of pharmaceutical development and manufacturing and recruited Jonathan Evans, previously of General Electric's Advanced Materials Division, to fill the role. Reporting to the chairman, president and CEO Thomas D'Ambra, Evans will now assume responsibility for Albany's Chemical Development, Small Scale cGMP Manufacturing, Analytical, Quality Control Quality Assurance, and Large Scale Commercial Manufacturing business components. India's Ranbaxy Laboratories has announced that Dr Himadri Sen will be joining the company as President of R&D. Prior to the appointment the firm had also Atul Sobti to Chief Operating Officer (COO) status and Peter Burema to the job of president of Global Pharmaceutical Business. Also in the news last week, privately-held Hyaluron Contract Manufacturing has promoted Paul Souza to the chief financial officer position, with responsibility for all financial operations, including investor relations. Meanwhile, IBS recently announced its global commitment to the pharmaceutical industry by appointing Andre Grigjanis as vice president of IBS Pharma to manage the company's worldwide activities for the sector. The new role includes marketing and sales coordination, training of sales and consultancy staff, and working with international pharma associations and business partners. IBS has developed a complete business software solution for pharmaceutical distributors and wholesalers, with new functionalities including electronic order reception, scanning throughout warehouse processes, batch control, and online connection to conveyor systems. "A key part of our global strategy for the pharmaceuticals industry is to ensure we are continually working on the important challenges for the market. These include the threats posed from counterfeiting and the need for effective track and trace and labelling capabilities," said Grigjanis. In other news, the Pharmaceutical Research and Manufacturers of America (PhRMA) has made changes to the board at the trade association's annual meeting last week. Kevin Sharer, CEO and president of Amgen, was re-elected chairman of the board - a position he assumed in September 2006; Merck CEO and president Richard Clark was named the board's chairman-elect; AstraZeneca CEO David Brennan was elected as the board's treasurer; and it was announced that Jeffrey Kindler, Pfizer chairman and CEO, is a new member of PhRMA's board of directors. And over in the Middle East, Globalpharma, a Dubai-based pharmaceutical manufacturing company and a subsidiary of Dubai Investments, has appointed Syed Jamil Akhtar as its new general manager. Akhtar was previously marketing director with Merck Sharp and Dohme in Saudi Arabia. Prior to that, Akhtar was the marketing manager for the Saudi Pharmaceutical Industries and Medical Appliances Corporation.
